

Discovery of Potent Hexapeptide Agonists to Human Neuromedin U Receptor 1 and Identification of Their Serum Metabolites

Kentaro Takayama,[†] Kenji Mori,[‡] Yuko Sohma,[†] Koji Taketa,[†] Akihiro Taguchi,[†] Fumika Yakushiji,[†] Naoto Minamino,[§] Mikiya Miyazato,[‡] Kenji Kangawa,[‡] and Yoshio Hayashi^{*,†}


[†]Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan

[‡]Department of Biochemistry and [§]Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan

S Supporting Information

ABSTRACT: Neuromedin U (NMU) and S (NMS) display various physiological activities, including an anorexigenic effect, and share a common C-terminal heptapeptide-amide sequence that is necessary to activate two NMU receptors (NMUR1 and NMUR2). On the basis of this knowledge, we recently developed hexapeptide agonists **2** and **3**, which are highly selective to human NMUR1 and NMUR2, respectively. However, the agonists are still less potent than the endogenous ligand, hNMU. Therefore, we performed an additional structure–activity relationship study, which led to the identification of the more potent hexapeptide **5d** that exhibits similar NMUR1-agonistic activity as compared to hNMU. Additionally, we studied the stability of synthesized agonists, including **5d**, in rat serum, and identified two major biodegradation sites: Phe²-Arg³ and Arg⁵-Asn⁶. The latter was more predominantly cleaved than the former. Moreover, substitution with 4-fluorophenylalanine, as in **5d**, enhanced the metabolic stability at Phe²-Arg³. These results provide important information to guide the development of practical hNMU agonists.

KEYWORDS: Agonist, biodegradation site, neuromedin U, neuromedin U receptor, peptide



Neuromedin U (NMU)¹ and S (NMS)² exhibit various biological behaviors, including appetite suppression,^{3,4} reduction in body weight,⁵ regulation of energy homeostasis,⁶ increase in body temperature,⁵ and regulation of glucose homeostasis.⁷ Recently, two-types of neuromedin U receptors (NMUR1 and NMUR2) were shown to be involved in the anorexigenic activity of peripherally administered human NMU (hNMU) conjugated with high molecular weight poly(ethylene)glycol (PEG) or human serum albumin (HSA).^{8,9} Accordingly, the pursuit of NMU-based drug development to treat obesity is considered promising. Mammalian NMU and NMS share the C-terminal heptapeptide-amide **1a** (H-Phe⁰-Leu¹-Phe²-Arg³-Pro⁴-Arg⁵-Asn⁶-NH₂, Figure 1A), which activates both receptors.^{1,2} In 1995, Hashimoto et al. reported that N-terminal succinylated **1a**, which was synthesized as an aminopeptidase-resistant derivative, showed potent contractile activity toward chicken crop smooth muscle expressing avian NMU receptors.¹⁰ Recently, we performed a structure–activity relationship (SAR) study of heptapeptide **1a** to develop receptor-selective agonists using cultured cells expressing human NMU receptors. As shown in Figure 1A, the results indicated that (1) the α -amino group at the N-terminal Phe⁰ residue in **1a** was not important for the agonistic activity because the N-terminal *des*-amino derivative,

1b, had similar activity to **1a**; (2) N-terminal 3-pyridylpropionyl (**1c**) and 3-cyclohexylpropionyl (**1d**) structures were important for selective agonistic activities toward NMUR1 and NMUR2, respectively; (3) bulky aromatic amino acid residues, e.g., Trp and naphthylalanine (Nal), at residue 1 (Leu¹) were important for both agonistic activity and selectivity toward NMUR1; (4) aliphatic amino acids, e.g., Leu, at residue 2 (Phe²), were important for both agonistic activity and selectivity toward NMUR2; and (5) α,β -diaminopropanoic acid (Dap) and α,γ -diaminobutyric acid (Dab) at residue 3 (Arg³) led to higher agonistic activity and selectivity toward NMUR2.¹¹ Furthermore, the structure of the C-terminal three amino acid residues, e.g., Pro⁴, Arg⁵, and Asn⁶-amide, was critical for the activation of both NMUR1 and NMUR2.¹¹ These results implied that the N-terminal structure could be modified to develop more potent and selective peptidomimetic agonists. Consequently, SAR studies based on the N-terminal structures of **1c** and **1d** successfully led to the discovery of hexapeptide derivatives **2** and **3** (Figure 1B), which selectively

Received: December 1, 2014

Accepted: January 28, 2015

Published: January 28, 2015




Figure 1. (A) Structures of human neuromedin U-derived peptides 1a–d and the SAR results from our previous study.¹¹ Arrows indicate the structural entities required for potent biological activity of the derivatives. (B) Structures of the NMUR1-selective agonist 2 and the NMUR2-selective agonist 3.¹¹

activate NMUR1 and NMUR2, respectively.¹¹ Particularly, the agonistic activity of hexapeptide 3 was amazingly selective to NMUR2, with no NMUR1 activation detected below 10^{-6} M; however, the agonistic activity of hexapeptide 3 was 3-fold less active than hNMU. However, the NMUR1 selectivity and potency of hexapeptide derivative 2 still had room for improvement, with an NMUR1-agonistic activity of about 10-fold less than that of hNMU. Therefore, in the present study, in order to develop more potent agonists, we performed additional SAR work and found agonist 5d, with potent activity and similar NMUR1-agonistic activity to hNMU. Moreover, we performed stability studies in rat and human serum to assess the biodegradation of the synthesized agonists and found that they were cleaved at two positions: Phe²-Arg³ and Arg⁵-Asn⁶. The amide bond of the Arg⁵-Asn⁶ site was more preferentially cleaved. In addition, a substitution of Phe² with the 4-fluorophenylalanine [Phe(4-F)²] in 5d enhanced metabolic stability at the Phe²-Arg³ site. These results will provide

important information to guide the development of a more metabolically stable peptidic hNMU agonist.

All peptide derivatives were synthesized by 9-fluorenylmethoxycarbonyl (Fmoc)-based solid-phase peptide synthesis as reported previously.¹¹ Constructed protected peptide resins were treated with trifluoroacetic acid (TFA)-*m*-cresol-thioanisole-1,2-ethanedithiol (EDT) (4.0 mL, 40:1:1:1) for 150 min at room temperature, and the resultant crude peptides were purified by preparative reversed-phase (RP)-HPLC. All peptide derivatives were characterized by electrospray ionization time-of-flight mass spectrometry (ESI-TOF MS) and key peptides were analyzed by NMR (see the Supporting Information). Each peptide had a purity of >95% as assessed by RP-HPLC analysis at 220 or 230 nm and was solubilized as a 20 mM stock solution in DMSO for subsequent bioassays. The agonistic activities of peptide derivatives for human NMUR1 and NMUR2 stably expressed in Chinese hamster ovary (CHO) cells were evaluated by calcium mobilization assays (see the Supporting Information). The results for each peptide are presented as a relative value (%) compared to the activity of hNMU at a concentration of 1000 nM.

In the present study, to decrease the interexperimental deviation in the screening of potent agonists toward human NMUR1 and NMUR2, we adopted a system in which these receptors were stably expressed in CHO cells. In our previous study employing a transient receptor expression system, one of the potent derivatives, 4a (Figure 2A, derivative 7a in ref 11), which was derivatized from 1c by substituting the Leu¹ residue with a Phe, displayed higher selectivity to NMUR1.¹¹ This result was reproduced in the stable receptor expression system (Figure 2B). Hence, we focused on derivative 4a and began by modifying its N-terminal 3-pyridylpropionyl group. When we introduced 3-(2-thienyl)propionyl and 2-thienylacetyl groups (Figure 2A), the corresponding derivatives, 4b and 4c, respectively, exhibited more potent agonistic activities toward NMUR1 and NMUR2 as compared to 4a (Figure 2B). However, the derivatives with other acyl groups, such as 3-phenylpropionyl (S1a), phenylacetyl (S1b), and acetyl (S1c), showed decreased activities (Figure S1, Supporting Information). These results suggested that the N-terminal thiophene ring played an important role for the activation of human NMU receptors. Therefore, we chose derivative 4c with a lower molecular weight for further modifications.

Next, we focused on residue 1 (Phe) of a 4a-type agonist. In the previous study, introducing the bulky aromatic 2-naphthylalanine (2-Nal) at residue 1 of derivative 2 improved both agonistic activity and selectivity toward NMUR1 as compared to derivative 1c (Figure 1A), which had Leu at that position.¹¹ To further increase the agonistic activity, we synthesized three 4c derivatives, 4d through 4f, bearing Trp (4d), 1-Nal (4e), and 2-Nal (4f) with a side chain similar or identical to residue 1 in derivative 2 (Figure 2A). As shown in Figure 2B, the Trp-bearing derivative, 4d, exhibited the highest agonistic activities to both receptors among this series of derivatives, including the original hexapeptide lead, 1b, and the NMUR1-selective agonist, 2. In particular, the agonistic activity of 4d to NMUR1 was very similar to that of hNMU.

Next, we modified residue 2 (Phe²) based on the structure of derivative 4d. Kurosawa et al. reported that substituting Phe with Tyr typically increased the contractile activity of avian smooth muscle.¹² However, in our previous evaluation of human NMU receptors, substitution with three kinds of aromatic amino acids, including Tyr, phenylglycine, and




Figure 2. (A) Structures of **4a–f**. The asterisk indicates that **4a** was previously reported.¹¹ (B) Effect of substitutions at the N-terminus (residue 0) and residue 1 on the agonistic activity in CHO cells toward stably expressed human NMUR1 (black bar) and NMUR2 (gray bar) as determined by the calcium mobilization assay. Peptide concentrations, 1 and 10 nM; positive control, hNMU (activity at 1000 nM = 100%).

homoPhe, at residue 2 decreased the agonistic activity.¹¹ Moreover, substitution with cyclohexylalanine (an aliphatic amino acid) increased selectivity for NMUR2 rather than NMUR1.¹¹ Therefore, derivatives **5a–d**, bearing a series of β -aromatic amino acids at residue 2, i.e., 2-thienylalanine (**5a**), His (**5b**), 4-pyridylalanine (**5c**), and Phe(4-F) (**5d**), were synthesized (Figure 3A). The agonistic activity of derivative **5a** toward NMUR1 slightly decreased by comparison with **4d**, whereas its activity toward NMUR2 was nearly maintained (Figure 3B). Derivatives **5b** and **5c**, bearing nitrogen-heteroaromatic amino acids at residue 2, showed lower




Figure 3. (A) Structures of **5a–d**. (B) Effect of substitutions at residue 2 on the agonistic activity in CHO cells toward stably expressed human NMUR1 (black bar) and NMUR2 (gray bar) as determined by the calcium mobilization assay. Peptide concentrations, 0.1 and 1 nM; positive control, hNMU (activity at 1000 nM = 100%).

agonistic activities toward both receptors as compared to **4d** (Figure 3B). Interestingly, introduction of a fluorine atom (**5d**) to the 4-position of Phe² in **4d** slightly increased the agonistic activities toward NMUR1 and NMUR2. Specifically, the activity toward NMUR1 was slightly higher as compared to hNMU at 0.1 nM (Figure 3B).

Then, to precisely compare the agonistic activities of derivative **5d** and hNMU, we evaluated their dose-dependencies and calculated EC₅₀ values and intrinsic activities (i.a.) toward both human NMU receptors (Figure 4). The EC₅₀ values of derivative **5d** toward NMUR1 and NMUR2 were 0.083 ± 0.01 nM (i.a. = 95%) and 2.6 ± 0.3 nM (i.a. = 82%), respectively. This represented a ~1.7-fold increase and a ~2.8-fold decrease in potency as compared to hNMU, which gave values of 0.14 ± 0.02 and 0.92 ± 0.2 nM, respectively. These results indicated that derivative **5d** was the most potent hexapeptide agonist to activate human NMUR1 to date. In addition, the observed relatively potent agonistic activity of hexapeptide **5d** to NMUR2 would also be an important feature for the development of practical antiobesity drugs, which may require the engagement of both human NMU receptors to




Figure 4. *In vitro* agonistic activity in CHO cells of hexapeptide derivative **5d** toward stably expressed human NMUR1 (A) and NMUR2 (B) as determined by the calcium mobilization assay. Peptide concentrations, 10⁻¹²–10⁻⁶ M; reference compound, hNMU. Data were determined in triplicate.

induce full anorexigenic activity from a peripheral administration of PEG- or HSA-conjugated hNMU.^{8,9}

Next, we examined the *in vitro* stability of derivative **5d** in rat serum to understand its metabolic degradation profile. As comparators, we also examined the derivatives **1a**, **1b**, and **4d**. These peptides were incubated in 25% rat serum at 37 °C,^{13,14} and metabolites at different time points were identified by RP-HPLC after extraction with a Sep-Pak C18 Plus cartridge (see the Supporting Information). RP-HPLC chromatograms showing a representative **5d** stability time course are shown in Figure 5A. After 10 min, a new peak appeared at a retention time of 43.7 min (**5d-m1**); after 30 min, another new peak, with a retention time of 61.2 min, was observed (**5d-m2**). We successfully determined the structures of these two metabolites by mass spectrometric analysis [**5d-m1** *m/z* 903.4091 (*M* + *H*)⁺ (calcd for C₄₃H₃₆FN₁₂O₇S 903.4099); and **5d-m2** *m/z* 494.1552 (*M* + *H*)⁺ (calcd for C₂₆H₂₅FN₃O₄S 494.1550); Figure 5B]. The results suggested that in rat serum the amide bond of derivative **5d** seemed to be preferentially cleaved at the C-terminal Arg⁵-Asn⁶ site and subsequently at the Phe²-Arg³ site. A similar metabolic profile was observed for derivatives **1b** and **4d** (Figure S2, Supporting Information). Their respective metabolites were **1b-m1** (3-phenylpropionyl-Leu¹-Phe²-Arg³-Pro⁴-Arg⁵-OH), **1b-m2** (3-phenylpropionyl-Leu¹-Phe²-OH),




Figure 5. (A) Analytical RP-HPLC chromatograms showing the time-dependent metabolic degradation of **5d** in 25% rat serum. An aliquot of each sample extracted by Sep-Pak C18 Plus cartridges was analyzed using a C18 reverse-phase column detected by UV at 220 nm. (B) The structures of the two major metabolites, **5d-m1** and **5d-m2**. (C) Recovery rates of intact peptides **1a**, **1b**, **4d**, and **5d** after incubation for 10 min in 25% rat serum. (D) Recovery rates of intact peptides, **1b-m1**, **4d-m1**, and **5d-m1** after incubation for 60 min in 25% rat serum. Data were determined in triplicate. n.s., not significant; **p* < 0.05 and ***p* < 0.005.

4d-m1 (2-thienylacetyl-Trp¹-Phe²-Arg³-Pro⁴-Arg⁵-OH), and **4d-m2** (2-thienylacetyl-Trp¹-Phe²-OH) (Figure S2, Supporting Information). No metabolites of **1a** were detected probably due to sequential degradation from the N-terminal-free amino acid residue by aminopeptidase. Additionally, we noted that a cleavage at the C-terminal Arg-Asn site was observed in hNMU under the same conditions (data not shown). Moreover, we examined the stability of derivative **5d** in human serum and observed a similar degradation pattern as that shown in rat serum (Figure S3, Supporting Information).

To better understand the metabolism, the recovery rates (%) of intact peptide derivatives **1a**, **1b**, **4d**, and **5d** at 10 min were determined (Figure 5C). At first, the N-terminal *des*-amino hexapeptide derivative, **1b**, which was designed to resist

aminopeptidase degradation,¹¹ showed improved serum stability (64.0 ± 1.5% recovery) as compared to the free N-terminal heptapeptide derivative, **1a** (37.0 ± 0.7% recovery). Contrary to our expectations, however, the recovery rate of the N-terminal acylated derivative, **4d**, like **1b**, was low (39.8 ± 2.1%) and similar to that of heptapeptide **1a**. However, the recovery rate of **5d** was slightly better (42.7 ± 1.9%) as compared to **1a**. These results suggested that the effect of the fluorine atom toward the metabolic stabilization of **4d** was not observed due to probable rapid degradation at the Arg⁵-Asn⁶ site.

Thus, to investigate the effect of the Phe(4-F)²-Arg³ bond on metabolic stability, three metabolites, **1b-m1**, **4d-m1**, and **5d-m1**, which did not include the metabolically unstable Arg⁵-Asn⁶ bond, were chemically synthesized and evaluated. As shown in Figure 5D, the recovery rate of **5d-m1** at 60 min (54.0 ± 2.9%) was significantly improved as compared to **4d-m1** (44.7 ± 0.6%) and was similar to **1b-m1** (56.9 ± 0.4%). These results suggested that (1) the cleavage rate of the Phe²-Arg³ bond was slower than that of the Arg⁵-Asn⁶ bond; (2) substitution with Phe(4-F) at residue 2 in **4d** enhanced the stability of the original Phe²-Arg³ bond; and (3) the structural changes in the three N-terminal moieties (acyl group, residues 1 and 2) from **1b** to **5d** promoted the cleavage rate of the Arg⁵-Asn⁶ bond because **5d** was more rapidly degraded than **1b** in spite of similar recovery rates between **1b-m1** and **5d-m1**.

In conclusion, this study clarified that (1) the novel hexapeptide derivative, **5d** (designated CPN-170; CPN, C-terminal core peptide derivative of neuromedin U) displayed potent agonistic activity toward human NMU receptors, especially NMUR1; (2) our hexapeptide derivatives were hydrolyzed at two major cleavage sites (the Arg⁵-Asn⁶ and Phe²-Arg³ bonds) in rat serum; (3) the Arg⁵-Asn⁶ bond was preferentially cleaved as compared to the Phe²-Arg³ bond; (4) introduction of a fluorine atom at the 4-position of Phe in **4d** significantly stabilized the Phe²-Arg³ bond; and (5) N-terminal structural modifications at the acyl group, residues 1 and 2 influenced not only the agonistic activity but also the metabolic stability of both cleavage sites. In practical terms, stabilization of the Arg⁵-Asn⁶ bond will be necessary to exert a long-lasting anorexigenic effect *in vivo*. Furthermore, to achieve innovative translational research based on NMUR1, the discovery of more potent and selective agonists beyond derivative **2** will be expected from future SAR studies based on hexapeptide derivative **5d**.

■ ASSOCIATED CONTENT

📄 Supporting Information

Materials, experimental procedure, analytical data for all peptide derivatives, analytical HPLC chromatograms, NMR spectra, and Figures S1–S3. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Tel: +81 42 676 3275. Fax: +81 42 676 3279. E-mail: yhayashi@toyaku.ac.jp.

Funding

This research was supported in part by the Japan Society for the Promotion of Sciences (JSPS) KAKENHI, including Grants-in-Aid for Scientific Research (B) 23390029 (to Y.H.) and 25293188 (to M.M.).

Notes

The authors declare no competing financial interest.

■ ABBREVIATIONS

α -MEM, Alfa Modified Eagle Minimum Essential Medium; BSA, bovine serum albumin; CHO, Chinese hamster ovary; CPN, C-terminal core peptide derivative of neuromedin U; Dab, α,γ -diaminobutyric acid; Dap, α,β -diaminopropanoic acid; DMSO, dimethyl sulfoxide; DIPCI, diisopropylcarbodiimide; DMF, dimethylformamide; EDT, 1,2-ethanedithiol; ESI, electrospray ionization; FCS, fetal calf serum; Fmoc, 9-fluorenylmethoxycarbonyl; HBSS, Hank's Balanced Salt Solution; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HOBt, 1-hydroxybenzotriazole; HSA, human serum albumin; i.a., intrinsic activity; Nal, naphthylalanine; NMS, neuromedin S; NMR, nuclear magnetic resonance; NMU, neuromedin U; NMUR1, neuromedin U receptor type 1; NMUR2, neuromedin U receptor type 2; Phe(4-F), 4-fluorophenylalanine; RP-HPLC, reversed phase high-performance liquid chromatography; SAR, structure–activity relationship; TFA, trifluoroacetic acid; TMS, tetramethylsilane; TOF MS, time-of-flight mass spectrometry

■ REFERENCES

- (1) Minamino, N.; Kangawa, K.; Matsuo, H. Neuromedin U-8 and U-25: Novel uterus stimulating and hypertensive peptides identified in porcine spinal cord. *Biochem. Biophys. Res. Commun.* **1985**, *130*, 1078–1085.
- (2) Mori, K.; Miyazato, M.; Ida, T.; Murakami, N.; Serino, R.; Ueta, Y.; Kojima, M.; Kangawa, K. Identification of neuromedin S and its possible role in the mammalian circadian oscillator system. *EMBO J.* **2005**, *24*, 325–335.
- (3) Kojima, M.; Haruno, R.; Nakazato, M.; Date, Y.; Murakami, N.; Hanada, R.; Matsuo, H.; Kangawa, K. Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3). *Biochem. Biophys. Res. Commun.* **2000**, *276*, 435–438.
- (4) Ida, T.; Mori, K.; Miyazato, M.; Egi, Y.; Abe, S.; Nakahara, K.; Nishihara, M.; Kangawa, K.; Murakami, N. Neuromedin S is a novel anorexigenic hormone. *Endocrinology* **2005**, *146*, 4217–4223.
- (5) Nakazato, M.; Hanada, R.; Murakami, N.; Date, Y.; Mondal, M. S.; Kojima, M.; Yoshimatsu, H.; Kangawa, K.; Matsukura, S. Central effects of neuromedin U in the regulation of energy homeostasis. *Biochem. Biophys. Res. Commun.* **2000**, *277*, 191–194.
- (6) Hanada, T.; Date, Y.; Shimbara, T.; Sakihara, S.; Murakami, N.; Hayashi, Y.; Kanai, Y.; Suda, T.; Kangawa, K.; Nakazato, M. Central actions of neuromedin U via corticotropin-releasing hormone. *Biochem. Biophys. Res. Commun.* **2003**, *311*, 954–958.
- (7) Peier, A. M.; Desai, K.; Hubert, J.; Du, X.; Yang, L.; Qian, Y.; Kosinski, J. R.; Metzger, J. M.; Poci, A.; Nawrocki, A. R.; Langdon, R. B.; Marsh, D. J. Effect of peripherally administered neuromedin U on energy and glucose homeostasis. *Endocrinology* **2011**, *152*, 2644–2654.
- (8) Ingallinella, P.; Peier, A. M.; Poci, A.; Marco, A. D.; Desai, K.; Zytko, K.; Qian, Y.; Du, X.; Cellucci, A.; Monteagudo, E.; Laufer, R.; Bianchi, E.; Marsh, D. J.; Pessi, A. PEGylation of neuromedin U yields a promising candidate for the treatment of obesity and diabetes. *Bioorg. Med. Chem.* **2012**, *20*, 4751–4759.
- (9) Neuner, P.; Peier, A. M.; Talamo, F.; Ingallinella, P.; Lahm, A.; Barbato, G.; Marco, A. D.; Desai, K.; Zytko, K.; Qian, Y.; Du, X.; Ricci, D.; Monteagudo, E.; Laufer, R.; Poci, A.; Bianchi, E.; Marsh, D. J.; Pessi, A. Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide. *J. Pept. Sci.* **2013**, *20*, 7–19.
- (10) Hashimoto, T.; Kurosawa, K.; Sakura, N. Structure-activity relationships of neuromedin U. II. High potent analogs substituted or

modified at the N-terminus of neuromedin U-8. *Chem. Pharm. Bull.* **1995**, *43*, 1154–1157.

(11) Takayama, K.; Mori, K.; Taketa, K.; Taguchi, A.; Yakushiji, F.; Minamino, N.; Miyazato, M.; Kangawa, K.; Hayashi, Y. Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2. *J. Med. Chem.* **2014**, *57*, 6583–6593.

(12) Kurosawa, K.; Sakura, N.; Hashimoto, T. Structure-activity relationships of neuromedin U. III. Contribution of two phenylalanine residues in dog neuromedin U-8 to the contractile activity. *Chem. Pharm. Bull.* **1996**, *44*, 1880–1884.

(13) Nguyen, L. T.; Chau, J. K.; Perry, N. A.; de Boer, L.; Zaat, S. A. J.; Vogel, H. J. Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. *PLoS One* **2010**, *5*, e12684.

(14) Powell, M. F.; Stewart, T.; Otvos, L., Jr.; Urge, L.; Gaeta, F. C. A.; Sette, A.; Arrhenius, T.; Thomson, D.; Soda, K.; Colon, S. M. Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. *Pharm. Res.* **1993**, *10*, 1268–1273.